University of Cape Town Lung Institute
11
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis
Role: collaborator
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Role: collaborator
Xpert Active Case-finding Trial 3 (XACT-3)
Role: collaborator
Stool Processing Kit (SPK) Evaluation for Pediatric Tuberculosis (TB)
Role: collaborator
Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).
Role: collaborator
A Randomized Controlled Trial of a Digital, Self-testing Strategy for COVID-19 Infection in South Africa.
Role: collaborator
Rapid and Accurate Diagnosis of Paediatric TB (RaPaed-AIDA-TB)
Role: collaborator
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
Role: collaborator
Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa
Role: collaborator
Study of Daily Rifapentine for Pulmonary Tuberculosis
Role: collaborator
Trial of Point-of-treatment Xpert MTB/RIF Assay
Role: collaborator
All 11 trials loaded